44 results about "Antagonists drugs" patented technology

The invention relates the method for forecasting the drug-effect. The method measures the polymorphism gene type to forecast the drug-effect of calcium antagonist drug. The method forecasts the drug-effect of calcium antagonist drug by measuring the polymorphism gene type of key enzyme gene on the aminothiopropionic acid metabolism path.; at the mean time, according to the effect, prepare the compound drug which can improve the drug-effect of calcium antagonist by adjusting the preparation of aminothiopropionic acid metabolism path. The invention improves the effective rate of clinical drug therapeutics and the safety of clinical drug, and reduces the drug toxin side effect and cost.

The present invention describes novel compounds of the formula:(Q)d-Ln-Ch,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and / or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and / or panic episode.

The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist. The invention provides methods for treating psychiatric condition or disorder or the symptoms thereof, including acute anxiety and panic comprising administering a pharmaceutical composition consisting essentially of a beta adrenergic receptor antagonist drug and an antiemetic muscarinic receptor antagonist drug in a therapeutically effective amount to stop or reduce the symptoms of anxiety and / or panic. The pharmaceutical compositions are administered as treatments immediately in advance of, at the onset of, or during an acute anxiety and / or panic episode.

The invention relates to a dihydroxydibenzo[b,f][1,5]dioxocane compound, a preparation method, a pharmaceutical composition and an application thereof, and belongs to the technical field of chemistry and medicine. The structure of the compound is shown in formula (I): formula (I). The compound is isolated from lichen red snow tea, and can significantly kill and / or inhibit various human cancer cells in vitro. In vivo, it has a significant inhibitory effect on the growth of transplanted tumors in mice. It has synergistic or additive combined anti-tumor effect with clinical anti-tumor drugs. The anticancer effect in vitro has obvious targeting and selectivity. It can affect the cycle distribution, gene expression, signaling pathway and function of cancer cells, and promote the apoptosis of cancer cells. It has no obvious toxicity to animals, and can significantly reduce the toxicity of cisplatin to animals. The compound of formula (I) can be used as a chemotherapeutic drug for human cancer, as a combination drug of other anticancer drugs, a toxicity antagonist drug or a health product for adjuvant cancer treatment.

Provided herein is a sandwich immunoassay for the detection of cross-linked PIIINPs having at least two PIIINP chains linked together by interchain crosslinks, each chain having N protease composed of intact type III procollagen C-terminal neo-epitopes of PIIINP generated by cleavage. A biological sample with cross-linked PIIINP is contacted with a first surface-bound monoclonal antibody, followed by a second monoclonal antibody, both of which are specifically reactive with the neo-epitope in the C-terminal sequence of PIIINP, and then Binding of the second monoclonal antibody was determined. Also provided is a method of assessing the efficacy of an antagonist drug targeting lysyl oxidase by an immunoassay and a kit comprising a solid support bound to a first monoclonal antibody and comprising a second monoclonal antibody.

The invention relates to a compound for treating hypertensive, particularly relating to a calcium ion antagonist drug complex with full dissolution, good stability and high bioavailability. The invention is characterized in that the complex contains (A) calcium channel antagonist, (B) alkaline excipient with effective dose and (C) non-ionic surfactant; wherein (A):(B):(C) is ranged from 0.1:1:1 to 10:1:1.

The invention relates to 1,2,3,4-tetrahydroquinoline compound and a synthetic method and application thereof. In a structure formula of the compound, the R1 is nitro or trifluoromethyl or 3-nitrophenylnitrobenzene sulfonyl or cyano, the R2 is hydrogen or methyl, the R3 is methyl formate or butyl formate, and the R4 is methyl. An aromatic ring of the 1,2,3,4-tetrahydroquinoline compound contains a series of electron withdrawing groups. The synthetic method is simple, economical, environment-friendly, easy to operate, easy to control, higher in product purity and yield and good in development prospect in industrial production; in addition, the synthetic method is also a novel synthetic method in atom economy; furthermore, the 1,2,3,4-tetrahydroquinoline compound can serve as intermediate to be used for preparing antagonist medicine.

The invention discloses a process for preparing an intermediate of zafirlukast, and the compound is an important intermediate for preparing the leukotriene antagonist drug zafirlukast. With (5-nitro-1-toluenesulfonyl-1H-indol-3-yl) methyl acetate and 3-methoxybenzoic acid methyl ester as raw materials, under the action of acidified montmorillonite, in an inert solvent In, heat the reaction until the raw materials disappear, filter to obtain 3-methoxy-4-[(5-nitro-1-toluenesulfonyl-1H-indol-3-yl) methyl] methyl benzoate; the above compound Under alkaline conditions, hydrolysis yields the target product. The invention provides a new process route for synthesizing an important intermediate of zafirlukast, which has the technical advantages of simple operation, low reaction cost, high product yield and environmental friendliness, and can meet the demand for large-scale production of pharmaceutical products.